Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 29:8:43-52.
doi: 10.2147/ITT.S202015. eCollection 2019.

Cytokine Release Syndrome: Current Perspectives

Hemant Murthy  1 , Madiha Iqbal  1 , Julio C Chavez  2 , Mohamed A Kharfan-Dabaja  1
Affiliations
Review

Cytokine Release Syndrome: Current Perspectives

Hemant Murthy et al. Immunotargets Ther. .

Abstract

Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel. Tisagenleclucel is also approved for relapsed and/or refractory B-ALL up to age 25. CART therapy is associated with unique and potentially life-threatening toxicities, notably cytokine release syndrome (CRS). A better understanding of the pathogenesis of CRS is crucial to ensure proper management. In this review, CRS definitions, profiles, risk factors and grading systems are discussed. Finally, current and novel investigational approaches and therapies for CRS are summarized.

Keywords: chimeric antigen receptor T-cell therapy; cytokine release syndrome.

PubMed Disclaimer

Conflict of interest statement

Professor Mohamed A Kharfan-Dabaja reports consultancy for Daiichi Sankyo and Pharmacyclics, outside the submitted work. Julio C Chavez reports consultancy for Kite/Gilead and Novartis and consultancy for Genentech, Bayer, and Karyopharm and speaker Bureau for Genentech. The authors report no other conflicts of interest in this work.

References

    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447 - DOI - PMC - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980 - DOI - PubMed
    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866 - DOI - PMC - PubMed
    1. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–1737. doi:10.1056/NEJMoa1817226 - DOI - PMC - PubMed
    1. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–126. doi:10.1111/imr.12131 - DOI - PMC - PubMed